SCM
ESPR

Sarissa Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Sarissa Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-633,000
Closed -$10.7M – 16
2016
Q1 		$10.7M Buy
633,000
+185,000
+41% +$2.98M 2.36% 9
2015
Q4 		$9.97M Hold
448,000
– – 1.94% 10
2015
Q3 		$10.6M Buy
+448,000
New +$28.1M 2.61% 10

Other funds holding ESPR

AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Sarissa Capital Management's ESPR Position: Q2 2016 in Review

Sarissa Capital Management sold out of Esperion Therapeutics (ESPR) in Q2 2016, closing a stake of 633,000 shares — an estimated $10.7M sold.

Sarissa Capital Management first reported a position in ESPR in Q3 2015 and held it in 3 quarters. The position peaked at $10.7M in Q1 2016. 102 funds tracked by Wall St. Rank hold ESPR as of Q2 2016.

  • Sarissa Capital Management reported no remaining Esperion Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Sarissa Capital Management sold 633,000 Esperion Therapeutics shares in Q2 2016, an estimated $10.7M.
  • Sarissa Capital Management first reported a position in Esperion Therapeutics in Q3 2015 and held it in 3 quarters.
  • Sarissa Capital Management's Esperion Therapeutics position peaked at $10.7M in Q1 2016.
  • 102 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2016.

Based on Sarissa Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.